Application of : M. PAIRET et al.) Art Unit: To be assigned U.S. Appln. No. : 10/613,783) Examiner: To be assigned Confirmation No.: To be assigned U.S. Filing Date : July 3, 2003 Title of Invention: PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND PDE-IV INHIBITORS Attny. Docket No.: 1/1192-1-C1 Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450 August 22, 2003 TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT Sir: Transmitted herewith concerning the subject application is an Information Disclosure Statement (Form 1449A/B) under 37 C.F.R. §§1.56 and 1.97, as more specifically described hereinbelow. \boxtimes 1.97(b). This Statement is being filed: i) within three (3) months of the filing date of a national application other than a continued prosecution application under 33 C.F.R. §1.53 (d); ii) within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; iii) before the mailing of a first Office action on the merits; or iv) before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. §1.114. This Statement is being filed after the time period specified in 37 1.97(c). C.F.R. §1.97(b), but before the mailing date of: i) a final action under 37 C.F.R. §1.113, ii) a notice of allowance under 37 C.F.R. §1.311, or iii) an action that otherwise closes prosecution in the application. This Statement is being accompanied by:

A statement as specified in 37 C.F.R. §1.97(e) [see below]; or

The fee set forth in 37 C.F.R. §1.17(p).

The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
1.97(d). This Statement is being filed after the period specified in 37 C.F.R. §1.97(c) but on or before payment of the issue fee. This Statement is accompanied by a statement as specified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R. §1.17(p).
1.97(e).
Each item of information contained in the instant information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of the instant information disclosure statement; or
No item of information contained in the instant information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this certification after making reasonable inquiry, no item of information contained in the instant information disclosure statement was known to any individual designated in 37 C.F.R §1.56(c) more than three (3) months prior to the filing of the instant information disclosure statement.
The fee set forth in 37 C.F.R. §1.17(p).
The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
1.704(d). Each item of information contained in the accompanying information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, which communication was not received by any individual designated in section 1.56(c) more than thirty (30) days prior to the filing of the accompanying information disclosure statement.

The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,

Mary-Ellen M. Devlin Attorney for Applicant(s)

Reg. No. 27,928

Patent Department
Boehringer Ingelheim Corp.
900 Ridgebury Road, P.O. Box 368
Ridgefield, CT 06877
Tel: (203) 708 4866

Tel: (203) 798-4866 Date: August 22, 2003 Certificate of Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner For Patents P. O. Box 1450 Alexandria, VA 22313-1450

on August 21, 2003.

Mary-Eller M. Devlin, Reg. No. 27,928

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for	or form 1449B/PTO	98/210		mplete if Known	
				Application Number	10/613,783
INFOR	KMATION L	SIC	CLOSURE	Filing Date	July 3, 2003
STATI	EMENT RY	' Δ	PPLICANT	First Named Inventor	Michel PAIRET et al
			I I LIOAIII	Group Art Unit	To be assigned
	(use as many shee	ets_a	s necessary)	Examiner Name	To be assigned
Sheet	2	of	22	Attorney Docket Number	1/1192-1-C1

Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	Γ
Examiner Initials	No.1	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue	'
		DISSE, B. et al: "BA 679 BR, A Novel Long-Acting Anticholinergic Bronchodilator: LIFE	╆
		SCIENCES, Pergamon Press, Oxford, GB, Bd. 5/6, Nr. 52, 1993, Seiten 537-544,	l
		XP008002589 ISSN: 0024-3205	
		BARNES, P.J.: "Nonantimicrobial Aspects of Therapy" SEMINARS IN RESPIRATORY INFECTIONS,	1
		Srune and Stratton, Orlando, US, Bd. 15, Nr. 1, 2000, Seiten 52-58 XP000911165, ISSN: 0882-0546, Seite 53, Spalte 1, Absatz 2 - Seite 56, Spalte 1, Zeile 20-40	
		TAVAKKOLI, A., REES, P.J.: "Drug Treatment of Asthma in the 1990s: Achievements and New Strategies" DRUGS, Bd. 57, Nr. 1, 1999, Seiten 1-8 XP001098314 ISSN: 0012-6667 Seite 3, Spalte 2, Abstaz 2; Seite 4, Spalte 2, Abstaz 2	
	J	DATA BASE WPI Derwent Publications Ltd., London, GB; AN 2001-626119 XP00221 <u>2897</u> MATSUMOTO, Tatsumi, TARUI, Naoki et al.: "New and Know Furoisoquinoline Compounds as Phosphodiesterase IV Inhibitors"	

			_
***************************************			1
·····			-
			1

-	Examiner	Date	
ı	Signature		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Control sumbor

troi number.				
Substitute for form 1449A/PTO	Complete if Known			
INFORMATION DISCUSSIONE	Application Number	10/613,783	_	
INFORMATION DISCLOSURE	Filing Date	July 3, 2003		
STATEMENT BY APPLICANT	First Named Inventor	Michel PAIRET et al		

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known		
Application Number	10/613,783	
Filing Date	July 3, 2003	
First Named Inventor	Michel PAIRET et al	
Art Unit	To be assigned	
Examiner Name	To be assigned	
Attorney Docket Number	1/1192-1-C1	

	U.S. PATENT DOCUMENTS				
Examiner Initials		Document Number Number - Kind Code ² (if known	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		us- 2002/0052312 A	105/02/2002	BACH, Mark A. et al	
enterence protectings and the law space.		∪s- 5,610,163	03/11/1997	R. Banholzer et al.	
************		us-			V
r:r:::100000000000000000000000000000000		us-		***************************************	***************************************
		US-			***************************************
Marie 11		US-			*
		US-	W		
		US-			
	4,744,7,7,10	US-			2000 to 1000 to
		US-	***************************************		***************************************
		US-			
		US-			
		US-			
	***************************************	US-	~		
······································	Campion (1999)	US-	**************************************		

		FOR	EIGN PATENT D	OCUMENTS		
Examiner Initials	Cite No. ¹	Foreign Patent Document Country Code3 -Number4 - Kind Code5 (if known)	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
*****		WO 01 78741 A1 🗸	10/25/2001	Glaxo Group Ltd.		İ
· · · · · · · · · · · · · · · · · · ·		WO 02 09689 A1 -	02/07/2002	Smithkline Beecham	The second secon	1
		WO 01 57025 A1 -	08/09/2001	Pfizer Products Inc.	entrol 6 11 to 15 11 to 15 15 to 15	
	***************************************	WO 01 46151 A1 ~	06/28/2001	Merck Frosst Canada	PRODUCTION P. ST. II. S.	
	Acres Concordos do	EP 1 040 829 A2 🗸	10/04/2000	Pfizer Inc.		
	~~ ~~~	WO 00/35428	06/22/2000	Boehringer Ingelheim Pharma KG		******
			***************************************	·····	···········	

Examiner	Date
Signature	Considered

English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.